ENWEI PHARMACEUTICAL

301331
23.711.13% ( -0.27 )
Delay Trading: Nov 16, 11:21:54

Valuation

Current ValuationThe current P/E ratio is 65.30, within the reasonable range, cheaper than 30.73% of the time in the past 3 years, and the industry ranks 120/222, the industry Median 22.14.

65.3xP/E
Stock price¥23.98Earnings per share¥0.37

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 22.14x
017345168

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 22.14x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
300558SZBETTA PHARMACEUTICALS
71.31x25.34%¥19.02B
002399SZHepalink
70.35x80.52%¥13.35B
300723SZApicHope
70.75x255.12%¥12.80B
300049SZFurui Co.,Ltd.
65.16x75.86%¥11.47B
002755SZASK PHARM
62.04x--¥11.33B
603538SHMenovo
63.14x--¥6.97B
002728SZTY PHAR.
71.03x181.25%¥4.68B
600628SHSNW
69.75x--¥4.11B
002644SZFoci Pharmaceutical
60.61x--¥3.75B
600222SHTaloph
69.77x--¥3.55B
301509SZKingchem
68.86x--¥3.11B
301331SZENWEI PHARMACEUTICAL
65.30x--¥2.47B
603079SHSHENGDA BIO-PHARM
63.61x--¥2.16B
300583SZSito Bio
72.31x--¥2.10B
002566SZYISHENG PHARM
75.67x--¥1.98B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.